Back to Authors

Lee, James

https://orcid.org/0000-0003-4917-4012

Mayo Clinic

Henry Ford Health

Citations 1

Sex-Based Differences in Outcomes With Percutaneous Transcatheter Repair of Mitral Regurgitation With the MitraClip System: Transcatheter Valve Therapy Registry From 2011 to 2017
Villablanca, Pedro , Vemulapalli, Sreekanth , Stebbins, Amanda , Dai, Dadi, So, Chak-Yu , Eng, Marvin H. , Wang, Dee Dee , Frisoli, Tiberio , Lee, James , Kang, Guson , Ibrahim, Homam , Staniloae, Cezar , Gaba, Prakriti , Lemor, Alejandro , Finn, Matthew , Leon, Martin B. , Villablanca, Pedro A , Lee, James C , Staniloae, Cezar , Lemor, Alejandro , Ramakrishna, Harish , Shah, Binita , Wang, Dee Dee , Szerlip, Molly , Williams, Mathew , O’Neill, William W. , Shah, Binita

Circulation: Cardiovascular Interventions | November 16, 2021 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/circinterventions.120.009374 Get It

Background: Women have a higher rate of adverse events after mitral valve surgery. We sought to evaluate whether outcomes after transcatheter edge-to-edge repair intervention by sex have similar trends to mitral valve surgery. Methods: The primary outcome was 1-year major adverse events defined as a composite of all-cause mortality, stroke, and any bleeding in the overall study cohort. Patients who underwent transcatheter edge-to-edge repair for mitral regurgitation with the MitraClip system in the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy registry were evaluated. Linked administrative claims from the Centers for Medicare and Medicaid Services were used to evaluate 1-year clinical outcomes. Associations between sex and outcomes were evaluated using a multivariable logistic regression model for in-hospital outcomes and Cox model for 1-year outcomes. Results: From November 2013 to March 2017, 5295 patients, 47.6% (n=2523) of whom were female, underwent transcatheter edge-to-edge repair. Females were less likely to have >1 clip implanted ( P <0.001) and had a lower adjusted odds ratio of device success (adjusted odds ratio, 0.78 [95% CI, 0.67–0.90]), driven by lower odds of residual mitral gradient <5 mm Hg (adjusted odds ratio, 0.54 [CI, 0.46–0.63]) when compared with males. At 1-year follow-up, the primary outcome did not differ by sex. Female sex was associated with lower adjusted 1-year risk of all-cause mortality (adjusted hazard ratio, 0.80 [CI, 0.68–0.94]), but the adjusted 1-year risk of stroke and any bleeding did not differ by sex. Conclusions: No difference in composite outcome of all-cause mortality, stroke, and any bleeding was observed between females and males. Adjusted 1-year all-cause mortality was lower in females compared with males.